The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner.
An Outcome professional served as lead banker in the sale of Annese & Associates. His knowledge of our industry, extensive contacts within it, and attention to all facets of the transaction proved invaluable. His care and commitment to the Annese shareholders, board, myself and by extension to all of our employees was simply outstanding.
The Outcome team got fully up to speed with all aspects of our technology and business, and could pitch our company’s story, and value proposition, as well as anyone. They researched a full list of potential acquirers in order to target those with high potential, and articulate the true value proposition for each target in very clear terms.
Outcome Capital’s knowledge and expertise were crucial in bringing this transaction to fruition. Outcome advised us on both the acquisition and the financing and exceeded all our expectations.
I was impressed by Outcome Capital’s thoughtful M&A strategy and process, which stemmed from their ability to capture the complexities of Beryllium’s scientific and business value propositions.
The Outcome Capital team was a committed and flexible partner that proved critical to a successful acquisition.
I have worked with Outcome Capital on multiple, complex transactions. They bring strategic insights and operational experience to the table like no other investment bankers I have ever worked with.
I knew Outcome by reputation, and they were the only group I felt comfortable engaging with and trusting with this deal. What they provided exceeded my expectations not only in value, but also in their conduct and earnestness. It was a pleasure doing business with Outcome Capital.
I thank the Outcome team for driving the Verrix acquisition to completion, for protecting our interests and for an excellent job in navigating the bumps along the way. The Outcome team ran a solid competitive process that caused the market to speak toward a transaction for the benefit of both buyer and seller.
September 13, 2021 Vancouver, British Columbia & Boston, MA. AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes […]Read More
June 17, 2021 09:40 AM Eastern Daylight Time BOSTON, MA–(BUSINESS WIRE)–Outcome Capital, a specialized advisory and investment banking firm that serves middle market companies in the life science and technology segments, today announced that Veranex, a newly formed concept-to-commercialization service provider dedicated to the medtech industry, has acquired Boston Healthcare Associates (BHA), a global strategy […]Read More
Outcome Capital Life Science Market Pulse September 2021 Click to view our LifeSciences Pulse NewsletterDownload